Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group

BACKGROUND: Constitutive activation of nuclear factor κB (NF-κB) is associated with poor prognosis. Irinotecan demonstrates single-agent activity in head and neck cancer but activates NF-κB, promoting cell survival and resistance. Bortezomib is a proteasome inhibitor that inactivates NF-κB. PATIENTS...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gilbert, Jill, Lee, Ju Whei, Argiris, Athanassios, Haigentz, Missak, Feldman, Lawrence Eric, Jang, Minyoung, Arun, Pattatheyil, Van Waes, Carter, Forastiere, Arlene A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3689864/
https://ncbi.nlm.nih.gov/pubmed/22791234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23046
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky